Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2018, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.
An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored.
The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 5, 4, 1, 4 and 1 respectively.
Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Actinic (Solar) Keratosis - Overview
Actinic (Solar) Keratosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Actinic (Solar) Keratosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
Athenex Inc
G&E Herbal Biotechnology Co Ltd
Laboratories Ojer Pharma SL
LEO Pharma A/S
Neonc Technologies Inc
Novartis AG
Oncology Research International Ltd
Promius Pharma LLC
Actinic (Solar) Keratosis - Drug Profiles
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
celecoxib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluorouracil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GDC-695 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ingenol disoxate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORIL-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOR-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VDA-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Actinic (Solar) Keratosis - Dormant Projects
Actinic (Solar) Keratosis - Discontinued Products
Actinic (Solar) Keratosis - Product Development Milestones
Featured News & Press Releases
Feb 20, 2018: Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting
Feb 14, 2018: Athenex Announces Early Completion of Patients Enrollment for Two Phase III Clinical Studies of KX2-391 Ointment for Actinic Keratosis
Dec 18, 2017: NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase II Clinical Trial of NanoPac Adding to Trials in Prostate and Ovarian Cancers
Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting
Oct 12, 2017: Vidac Pharma Reports Positive Results from Phase 2a Proof-of-Concept Trial of VDA-1102 Ointment in Actinic Keratosis
Sep 26, 2017: DFB Soria Gives Update on Enrollment in Phase 2 Clinical Trial of SOR007 (Nanoparticle Paclitaxel) Ointment for Actinic Keratosis (AK)
Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis
Dec 12, 2016: Vidac Pharma Phase 2 Study Of VDA-1102 In Actinic Keratosis Meets Interim Analysis Criterion
Jul 29, 2016: Vidac Pharma Announces The Innitiation Of A Phase 2 Study Of VDA-1102 Ointment In Patients With Actinic Keratosis
Jun 30, 2016: Vidac Pharma Completes Phase 1A Trial Of VDA-1102 Ointment
Feb 25, 2016: Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator
Dec 30, 2015: Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Actinic (Solar) Keratosis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Actinic (Solar) Keratosis - Pipeline by Athenex Inc, H1 2018
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2018
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, H1 2018
Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H1 2018
Actinic (Solar) Keratosis - Pipeline by Neonc Technologies Inc, H1 2018
Actinic (Solar) Keratosis - Pipeline by Novartis AG, H1 2018
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, H1 2018
Actinic (Solar) Keratosis - Pipeline by Promius Pharma LLC, H1 2018
Actinic (Solar) Keratosis - Dormant Projects, H1 2018
Actinic (Solar) Keratosis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Actinic (Solar) Keratosis - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Actinic (Solar) Keratosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
